Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.7K

Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB

A Chhibber1, J Mefford2, E A Stahl3

  • 11] Departments of Bioengineering and Therapeutic Sciences, University of California at San Francisco, San Francisco, CA, USA [2] Institute for Human Genetics, University of California at San Francisco, San Francisco, CA, USA.

The Pharmacogenomics Journal
|February 12, 2014
PubMed

Insights

Paclitaxel treatment can cause peripheral neuropathy, a nerve damage side effect. This study suggests a genetic component to this neuropathy, potentially linked to genes affecting axon outgrowth.

Area of Science:

  • Oncology
  • Genetics
  • Neuroscience

Background:

  • Peripheral neuropathy is a frequent dose-limiting side effect of paclitaxel chemotherapy.
  • The underlying causes and individual risk factors for paclitaxel-induced peripheral neuropathy (PIPN) remain largely unknown.
  • Identifying a heritable component of PIPN could inform clinical management and elucidate toxicity mechanisms.

Purpose of the Study:

  • To investigate the potential heritability of paclitaxel-induced peripheral neuropathy.
  • To explore genetic factors contributing to susceptibility to PIPN.
  • To gain insights into the mechanisms of PIPN.

Main Methods:

  • Analysis of genotype and clinical data from the paclitaxel arm of the CALGB 40101 (Alliance) phase III clinical trial.
  • Estimation of the variance in maximum grade and dose at the first occurrence of sensory peripheral neuropathy.
  • Utilizing data from breast cancer patients treated with adjuvant paclitaxel therapies.

Main Results:

  • The study provides evidence suggesting a significant heritable component to paclitaxel-induced peripheral neuropathy.
  • Genetic factors, particularly those influencing axon outgrowth, appear to contribute to PIPN susceptibility.
  • Variance in neuropathy severity and onset was analyzed in relation to patient genetic information.

Conclusions:

  • Paclitaxel-induced peripheral neuropathy likely has a genetic basis.
  • Disruption of axon outgrowth pathways may be a key mechanism underlying PIPN in susceptible individuals.
  • Understanding the heritable component can aid in predicting and potentially mitigating PIPN during paclitaxel therapy.

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

3.1K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.5K

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.2K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81